Connective Tissue Manipulation Improves Symptoms and Quality of Life in Patients With Chronic Constipation

October 4, 2018 updated by: Ceren Gürşen, Hacettepe University

Connective tissue manipulation (CTM) is a manual reflex therapy, which increases intestinal motility by stimulating autonomic nervous system to re-balance the parasympathetic and sympathetic functions. However, there is no randomized controlled trial (RCT) regarding the efficacy of CTM on constipation. This study was planned to investigate the effects of CTM in patients with chronic constipation.

Patients who have diagnosis of chronic constipation according to Rome III criteria were recruited and randomized to intervention and control group. The intervention group received CTM in addition to the lifestyle advice, while the control group was given only lifestyle advice for constipation. All assessments were performed at baseline and at the end of 4 weeks. The primary outcome measure was the Constipation Severity Instrument (CSI). Secondary outcomes included Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL), Bristol Stool Scale (BSS) and 7-day bowel diary. Differences between groups were analyzed with t-tests, Mann-Whitney U test and Chi-square test.

Study Overview

Detailed Description

In this prospective randomized controlled trial, informed consent forms were obtained from all participants and they were informed about the study based on the Declaration of Helsinki. The study was approved by local ethics committee of Hacettepe University (LUT 12/35-48). After comprehensive clinical evaluation, subjects were randomly assigned to the intervention group or the control group, using stratified block randomization procedure with blocks of four, using opeque and sealed envelopes, containing group allocation number from a computer generated random number table The intervention group received CTM in addition to the lifestyle advice, while the control group was given only lifestyle advice for constipation.

Patients diagnosed with chronic constipation by a based on Rome III Criteria were recruited by a gastroenterologist from Hacettepe University, Adult Hospital, Gastroenterology Unit and the patients were evaluated and treated at Hacettepe University, Faculty of Health Sciences, Physiotherapy and Rehabilitation Department, Women's Health Unit.

Participants were recruited if they were over 18 years of age and had a diagnosis of chronic constipation according to Rome III criteria. Exclusion criteria were comorbid neurological, anatomical, or metabolic condition, pregnancy, mental problems preventing cooperation, history of colostomy surgery, history of gastrointestinal, spinal, or pelvic surgery except cholecystectomy, appendectomy, or hysterectomy, comorbid various colonic conditions (intestinal obstruction, peritonitis, bowel perforation, peptic ulcer, gastrointestinal bleeding, or acute inflammation of abdominal organs), history of intestinal cancer, existence of open sore or tumor at the massage region, and abdominal hernia. Patients taking laxatives were excluded or were asked to discontinue the drug two weeks before enrollment.

Intervention CTM was applied five days per week, a total of 20 sessions for 4 weeks. Each session lasted around 15-20 minutes. While patients were in a sitting position, starting from the lumbosacral region, lower thoracic, scapular, inter-scapular and cervical regions were included in the treatment, respectively. All patients were also advised to increase their physical activity levels, fluid and fibre intake, and to take the ideal posture for defecation (squatting position) with a two-pages document.

Evaluations Physical (age, gender, Body Mass Index (BMI)(kg/m²) and demographic (educational status, duration of constipation, marital status, employment status) data of the participants were recorded. In addition, the number of meals per day, daily amount of liquid consumption, and physical activity levels were recorded. The participants' physical activity levels were measured using the Turkish version of the International Physical Activity Questionnaire-Short Form (IPAQ-SF). Measurements were performed at baseline and immediately after the treatment. All patients were evaluated by the same experienced therapist, who was blinded to the results of the pre-treatment measurements (CG).

The primary outcome measure

*Constipation Severity Instrument (CSI) To evaluate the severity of the participants' constipation, Constipation Severity Instrument (CSI) was used. CSI was designed to evaluate individuals' defecation frequency and consistency as well as the level of straining experienced by individuals during bowel movement. There are three subscales of CSI, obstructive defecation (OT), colonic inertia (CI), and pain. Higher scores of CSI indicate more severe constipation. Kaya et al. showed that the Turkish version of CSI is reliable and valid in determining constipation and grading of its severity.

Secondary outcome measures

  • Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) includes a total of 28 items in 4 subscales: worries and concerns (11 items), physical discomfort (4 items), psychosocial discomfort (8 items), and satisfaction (5 items). Higher scores of PAC-QOL indicate more negative effects of constipation on the quality of life. Turkish version of PAC-QOL was demonstrated to be reliable and valid.
  • Bristol Stool Scale (BSS) The stool consistency was evaluated using the Bristol Stool Scale (BSS), a seven-point scale (from 1 to 7), where 1 =separate hard lumps, like nuts; 2=sausage shaped but lumpy; 3 = like a sausage or snake, but with cracks on its surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear cut edges; 6=fluffy pieces with ragged edges, a mushy stool; 7=water, no solid pieces.
  • 7-Day Bowel Diary In order to gather information regarding the participants' symptoms of constipation, they were asked to complete a 7-day bowel diary before and after the treatment. This diary included items regarding the frequency of bowel movement, stool consistency, defecation time, feeling of incomplete evacuation, and changes in food and liquid consumption.
  • Perception of Subjective Change Individuals' perception of subjective change after the treatment was evaluated using a 5-point Likert-type scale: 0: No change, 1: Minimal change, 2: Moderate change, 3: Important change, 4: Very important change.
  • Compliance to the Advices Compliance of the participants to lifestyle advices was evaluated using a 4-point Likert-type scale: 0: No compliance, 1: minimal compliance, 2: moderate compliance, and 3: Full compliance.

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Ankara, Turkey, 06100
        • Hacettepe University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Participants were recruited if they were over 18 years of age and had a diagnosis of chronic constipation according to Rome III criteria.

Exclusion Criteria:

  • Exclusion criteria were comorbid neurological, anatomical, or metabolic condition, pregnancy, mental problems preventing cooperation, history of colostomy surgery, history of gastrointestinal, spinal, or pelvic surgery except cholecystectomy, appendectomy, or hysterectomy, comorbid various colonic conditions (intestinal obstruction, peritonitis, bowel perforation, peptic ulcer, gastrointestinal bleeding, or acute inflammation of abdominal organs), history of intestinal cancer, existence of open sore or tumor at the massage region, and abdominal hernia. Patients taking laxatives were excluded or were asked to discontinue the drug two weeks before enrollment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: intervention
we will apply connective tissue manipulation and life style advice.
We will apply connective tissue manipulation 5 days a week for four weeks.
We will apply life style advice for four weeks.
Other: control group
We will apply only life style advice.
We will apply life style advice for four weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Constipation Severity Instrument (CSI)
Time Frame: Participants will be followed for four weeks. Change from baseline severity of constipation at 4 weeks will be evaluated.
Constipation Severity Instrument was designed to evaluate individuals' defecation frequency and consistency as well as the level of straining experienced by individuals during bowel movement. There are three subscales of CSI, obstructive defecation (OT), colonic inertia (CI), and pain. Higher scores of CSI indicate more severe constipation.
Participants will be followed for four weeks. Change from baseline severity of constipation at 4 weeks will be evaluated.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient-Assessment of Quality of Life Questionnaire (PAC-QOL)
Time Frame: Participants will be followed for four weeks. Change from baseline quality of life at 4 weeks will be assessed.
Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) includes a total of 28 items in 4 subscales: worries and concerns (11 items), physical discomfort (4 items), psychosocial discomfort (8 items), and satisfaction (5 items).
Participants will be followed for four weeks. Change from baseline quality of life at 4 weeks will be assessed.
Bristol Stool Scale
Time Frame: Participants will be followed for four weeks. Change from baseline stool consistency at 4 weeks will be assessed.
The stool consistency was evaluated using the Bristol Stool Scale (BSS), a seven-point scale (from 1 to 7), where 1 =separate hard lumps, like nuts; 2=sausage shaped but lumpy; 3 = like a sausage or snake, but with cracks on its surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear cut edges; 6=fluffy pieces with ragged edges, a mushy stool; 7=water, no solid pieces.
Participants will be followed for four weeks. Change from baseline stool consistency at 4 weeks will be assessed.
7-day bowel diary
Time Frame: Participants will be followed for four weeks. Change from baseline symptoms of constipation at 4 weeks will be evaluated.
This diary included items regarding the frequency of bowel movement, stool consistency, defecation time, feeling of incomplete evacuation, and changes in food and liquid consumption.
Participants will be followed for four weeks. Change from baseline symptoms of constipation at 4 weeks will be evaluated.
perception of subjective change
Time Frame: Participants will be followed for four weeks. Change of subjective change from baseline after 4 week treatment will be assessed.
Individuals' perception of subjective change after the treatment was evaluated using a 5-point Likert-type scale: 0: No change, 1: Minimal change, 2: Moderate change, 3: Important change, 4: Very important change.
Participants will be followed for four weeks. Change of subjective change from baseline after 4 week treatment will be assessed.
compliance with advice
Time Frame: Participants will be followed for four weeks. Change of compliance with advice from baseline after 4 week treatment will be assessed.
Compliance of the participants to lifestyle advices was evaluated using a 4-point Likert-type scale: 0: No compliance, 1: minimal compliance, 2: moderate compliance, and 3: Full compliance.
Participants will be followed for four weeks. Change of compliance with advice from baseline after 4 week treatment will be assessed.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ceren Gursen, Hacettepe University
  • Study Director: Mintaze Kerem Gunel, Hacettepe University
  • Principal Investigator: Serap Kaya, Hacettepe University
  • Study Director: Taylan Kav, Hacettepe University
  • Study Chair: Türkan Akbayrak, Hacettepe University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2012

Primary Completion (Actual)

July 1, 2015

Study Completion (Actual)

July 1, 2015

Study Registration Dates

First Submitted

December 9, 2014

First Submitted That Met QC Criteria

December 16, 2014

First Posted (Estimate)

December 22, 2014

Study Record Updates

Last Update Posted (Actual)

October 9, 2018

Last Update Submitted That Met QC Criteria

October 4, 2018

Last Verified

October 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Hacettepe University (Hacettepe University)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Constipation

Clinical Trials on connective tissue manipulation

3
Subscribe